Inhibikase Therapeutics, Inc.
IKTHealthcareNASDAQBiotechnology · Last scanned Oct 27, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Inhibikase Therapeutics, Inc. focuses on Biotechnology services and products. Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a. The $227.4M market capitalization puts IKT squarely in micro-cap range for its industry. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
Market Cap
$227.4M
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-3.88
EPS (TTM)
$-0.43
EPS (Fwd)
$-0.42
ROE
-52.0%
ROA
-32.8%
Cash
$159.0M
Total Debt
$0
Free CF
-$22.1M
52W Change
6.5%
Annual Financials
Cash vs Debt
Where IKT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IKT finished 17.50% below its 150-day moving average ($2.00) and 15.38% below its 200-day moving average ($1.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IKT overbought or oversold?
At the October 20, 2026 close, IKT's RSI(14) was 27.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Inhibikase Therapeutics, Inc. reports $159.0M in cash and $0 in total debt. Free cash flow is running at -$22.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -52.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Inhibikase Therapeutics, Inc.'s trajectory.